The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…

Neupogen

In Amgen-Sandoz SCOTUS case, biosim makers lambaste ruling's 6-month exclusivity gift

UPDATED: UnitedHealth adds to formulary pain for Sanofi, Amgen and Novartis

Aiming to shield $14B in sales, AbbVie smacks Amgen with a patent suit over Humira biosim